Theravance Biopharma
TBPH
119 hedge funds and large institutions have $449M invested in Theravance Biopharma in 2021 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 24 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 21
88% more call options, than puts
Call options by funds: $8.44M | Put options by funds: $4.48M
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
10% more funds holding
Funds holding: 108 → 119 (+11)
1.85% less ownership
Funds ownership: 84.41% → 82.56% (-1.8%)
49% less capital invested
Capital invested by funds: $882M → $449M (-$433M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$55.1M |
| 2 |
BG
Baupost Group
Boston,
Massachusetts
|
+$41.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.1M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$28M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$94.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$90.8M |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
-$20.1M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$11.9M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$10.6M |
TBPH Hedge Fund Activity: Q3 2021 in Review
119 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2021, worth a combined $449M — down 49% from $882M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TBPH positions and 24 closed out — a net gain of 12 holders — while 42 added to existing stakes and 21 trimmed.
The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $55.1M. The largest seller was Wellington Management Group, cutting an estimated $94.8M.
- 119 institutional investors held Theravance Biopharma (TBPH) as of Q3 2021, up from 108 in Q2 2021.
- Funds reported $449M of Theravance Biopharma stock for Q3 2021, down 49% quarter-over-quarter.
- 36 funds opened new Theravance Biopharma positions in Q3 2021 and 24 closed out, a net change of +12 holders.
- The largest Theravance Biopharma buyer in Q3 2021 was Madison Avenue Partners, an estimated $55.1M added.
- The largest Theravance Biopharma seller in Q3 2021 was Wellington Management Group, an estimated $94.8M sold.
Based on aggregated 13F filings for Q3 2021.